11/6/2008

Cephalon will invest $20 million in Acusphere, gaining an exclusive worldwide license to AI-525 -- an injectable version of celecoxib, an anti-inflammatory drug. The investment also allows Cephalon to license Acusphere's blood-imaging agent Imagify, which is pending FDA approval.

Related Summaries